Photo: nasdaq.com
Tezspire Gains EU Nod for Severe Nasal Polyps Treatment by AstraZeneca, Amgen
AstraZeneca and Amgens Tezspire gains approval from the European Union as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, expanding treatment options for affected patients.
- Tezspire (tezepelumab) has received approval from the European Union as an adjuvant therapy for adult patients suffering from severe chronic rhinosinusitis with nasal polyps.
- The treatment is intended for individuals who have not sufficiently responded to standard interventions, including systemic corticosteroids and/or surgery, impacting approximately 320 million people globally.
- By targeting inflammation associated with nasal polyp development, Tezspire aims to provide a new management option for chronic sinusitis, enhancing patient care in this area.
Why It Matters
The approval of Tezspire signifies a major advancement in addressing a prevalent health issue, offering hope to patients with severe nasal polyps who have limited treatment options. This development reflects ongoing innovation in the pharmacological management of chronic sinusitis and related conditions.